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Abstract
Purpose This observational case registry study was designed to describe the natural history of cancer patients with medication-
related osteonecrosis of the jaw (ONJ) and evaluate the ONJ resolution rate.
Methods Adults with a diagnosis of cancer and with a new diagnosis of ONJ were enrolled and evaluated by a dental specialist at
baseline and every 3 months for 2 years and then every 6 months for 3 years until death, consent withdrawal, or loss to follow-up.
The primary endpoint was the rate and time course of ONJ resolution. Secondary endpoints included frequency of incident ONJ
risk factors, ONJ treatment patterns, and treatment patterns of antiresorptive agents for subsequent ONJ.
Results Overall, 327 patients were enrolled; 207 (63%) were continuing on study at data cutoff. Up to 69% of evaluable patients
with ONJ had resolution or improvement during the study. ONJ resolution (AAOMS ONJ staging criteria) was observed in 114
patients (35%); median (interquartile range) time from ONJ onset to resolution was 7.3 (4.5–11.4) months. Most patients (97%)
had received antiresorptive medication before ONJ development, 9 patients (3%) had not; 68% had received zoledronic acid,
38% had received denosumab, and 10% had received pamidronate (56% had received bisphosphonates only, 18% had received
denosumab only, and 21% had exposure to both).
Conclusions These results are consistent with those observed in clinical trials evaluating skeletal-related events in patients with
advanced malignancy involving bone. Longer follow-up will provide further information on ONJ recurrence and resolution rates
between medically and surgically managed patients.
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Introduction
Medication-related osteonecrosis of the jaw (ONJ) is an ad-
verse drug reaction resulting in the progressive destruction of
bone in the maxillofacial region [1–10]. Treatment of ONJ is
typically challenging for physicians. Management depends on
disease stage and can include conservative (e.g., oral rinses
and antibiotics) or minimally invasive approaches (e.g.,
sequestrectomy, debridement), and major surgical interven-
tion (e.g., resection) [4, 10, 11], as well as discontinuation of
the antiresorptive agent [10]. The goals of therapy for ONJ are
to support continued oncologic therapy (largely because on-
cologic medications outweigh the risk, incidence, and/or evo-
lution of ONJ lesions) and to control infection, pain, and pro-
gression of bone necrosis [1, 10]. Historically, ONJ has been
defined by the American Association of Oral and
Maxillofacial Surgeons (AAOMS) as medication-induced
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exposition of bone in the maxillofacial region that does not
heal within 8 weeks (in the absence of radiation of the jaw) [4,
10, 12], with the revised 2014 definition including bone that
can be probed through a fistula [10].More recently, it has been
suggested that the definition of ONJ should include nonex-
posed ONJ, which does not fulfill the current definition of
ONJ [13–15]. There is a need to establish globally accepted
criteria for nonexposed ONJ.
Antiresorptive bone-targeted agents such as nitrogenous
bisphosphonates, which act on bone metabolism by bind-
ing and blocking the enzyme farnesyl diphosphate syn-
thase in the HMG-CoA reductase pathway (i.e., the
mevalonate pathway), and denosumab, the first receptor
activator of nuclear factor-kappa β ligand inhibitor to be
approved by the US Food and Drug Administration, sup-
press bone turnover and are used to prevent bone compli-
cations (i.e., skeletal-related events [SREs]) in patients
with solid tumors that have bone metastasis. However,
these agents have been associated with a risk of developing
ONJ [10–12, 16–23]. Time of exposure, number of treat-
ments, duration of therapy, and cumulative dosage with
antiresorptive therapies have been shown to increase the
risk for developing ONJ [17, 24–27]. Development of
ONJ may also occur more frequently in patients treated
with intravenous bisphosphonates, compared with those
given oral bisphosphonates (13- to 15-fold difference in
risk) [28, 29]. Cofactors for increased risk of developing
ONJ with antiresorptive therapies include concurrent in-
flammatory periodontal disease [16, 30–32], dental trauma
(e.g., dental extraction, surgery to jawbones) [11, 12, 28,
30, 31, 33–37], and tobacco use [29, 34]. ONJ has also
been reported in patients receiving antiangiogenic thera-
pies such as bevacizumab [38, 39], sunitinib [40, 41], so-
rafenib [42], and cabozantinib [43].
Although the incidence of and risk factors associated
with ONJ are well established, at present, there is limited
information describing how ONJ is managed in routine
clinical practice or resolution rates after such treatment.
To this end, this observational case registry study was
designed in line with STROBE guidance for epidemiology
studies to describe the natural history of cancer patients
with ONJ and evaluate the rate of ONJ resolution, partic-
ularly in comparison with rates previously observed in
phase 3 clinical trials of SREs in patients with advanced
cancer and bone metastasis receiving antiresorptive thera-
py [21, 22, 25, 44].
Methods
The ONJ case registry is a case-series prospective follow-up
study of positively adjudicated ONJ cases. All patients pro-
vided informed consent.
Patients
Adults (aged ≥ 18 years) with a diagnosis of cancer and with a
new diagnosis of ONJ were identified by physicians at inter-
national cancer centers and underwent evaluation by a dental
specialist to assess the suspected ONJ. Information derived
from these examinations was then sent to an independent,
external adjudication committee for diagnosis confirma-
tion or rejection. Diagnosis was based on the AAOMS
updated 2014 criteria for staging of medication-related
ONJ (Table 1) and included patients with fistula tract
but without frank bone exposure [10]. The external adju-
dication committee comprised experts in the field of ONJ
diagnosis and treatment, and an oncologist and endocri-
nologist served as consultant experts as needed by adju-
dicators. Patients were considered eligible if they had
newly diagnosed (defined as diagnosed within 6 months
of existence) [10], positively adjudicated ONJ; had an
Eastern Cooperative Oncology Group (ECOG) perfor-
mance status ≤ 2 with expected survival ≥ 3 months; were
willing to provide access to previous and future medical
and dental information; and provided written informed
consent. Patients were excluded if they had a history of
radiation to the maxillofacial area, were unavailable for
Table 1 2014 American
Association of Oral and
Maxillofacial Surgeons staging of
medication-related osteonecrosis
of the jaw [10]
Stage Description
0 No clinical evidence of necrotic bone, but non-specific clinical findings, radiographic changes, and
symptoms
1 Exposed and necrotic bone, or fistulae that probe to bone, in patients who are asymptomatic and have no
evidence of infection
2 Exposed and necrotic bone, or fistulae that probe to bone, associatedwith infection as evidenced by pain
and erythema in the region of the exposed bone with or without purulent drainage
3 Exposed and necrotic bone, or fistulae that probe to bone, in patients with pain, infection, and one or
more of the following: exposed and necrotic bone extending beyond the region of alveolar bone (i.e.,
inferior border and ramus in the mandible, maxillary sinus, and zygoma in the maxilla) resulting in
pathologic fracture, extra-oral fistula, oral antral/oral nasal communication, or osteolysis extending to
the inferior border of the mandible or sinus floor
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protocol-required study visits, or had any disorder that
would have compromised the ability to give written in-
formed consent and/or to comply with study procedures.
Patients were permitted to receive antiresorptive treat-
ments such as bisphosphonates (oral or intravenous) or
denosumab at enrollment and during the study. It is im-
portant to note that the study protocol initially aligned
with the AAOMS 2009 criteria, which allowed for pa-
tients with ONJ and prior radiation to the maxillofacial
area for palliative indications to be enrolled in the study
[2]. However, the criteria were revised in the 2014
AAOMS position paper, and patients that had received
any radiation to the maxillofacial region were subsequent-
ly excluded from participation in the study [10]. As a
result, 14 patients (4.3%) received radiation to the maxil-
lofacial area for palliative indications in this study.
Study design
Study enrollment was planned to continue until approxi-
mately 300 patients with positively adjudicated ONJ were
enrolled, including approximately 75 patients who were
treated with denosumab as the only antiresorptive treat-
ment. A sample size of 300 patients was expected to yield
an ONJ resolution rate (defined as complete coverage of
the exposed bone by mucosa in the absence of clinical
symptoms) of 30% with a 95% CI of 25 to 35%. The
30% predicted ONJ resolution rate was based on rates ob-
served in prior clinical trials [21]. Patients with newly di-
agnosed ONJ were evaluated by a study dental specialist at
baseline (i.e., enrollment) with follow-up assessments ev-
ery 3 months for 2 years and then every 6 months for
3 years until death, withdrawal of consent, or loss to fol-
low-up. The protocol allowed for standard-of-care ONJ
treatment to be administered at the study sites, which was
generally defined as the best course of treatment for each
patient as determined by local dental and healthcare pro-
fessionals and international or local treatment guidelines.
Statistical analysis
The primary endpoint of this study was the rate and time
course of ONJ resolution (defined as complete coverage of
exposed bone by mucosa, without the ability to probe necrotic
bone, in the absence of clinical symptoms; radiological find-
ings were not included as part of resolution assessment).
Secondary endpoints included frequency of risk factors for
incident ONJ, treatment patterns for ONJ, and treatment pat-
terns of antiresorptive agents for subsequent ONJ. Data were
summarized using descriptive statistics (i.e., mean and stan-
dard deviation for continuous variables and frequency for cat-
egorical variables).
Results
Patients
Between 1 October 2012 and 4 April 2016, 327 patients were
enrolled from 64 study sites in North America and Europe.
The data cutoff date for this analysis was 28 April 2016.
Overall, 207 patients (63%) were continuing on study at the
data cutoff date; 120 patients (37%) had discontinued the
study. Reasons for study discontinuation included death (n =
73), withdrawn consent (n = 17), loss to follow-up/noncom-
pliance (n = 13), disease (cancer) progression (n = 8), admin-
istrative decision (n = 6), and study site closure (n = 3). The
median (interquartile range [IQR]) length of follow-up after
enrollment was 11.2 (6.3–17.3) months (mean [SD] was 12.6
(7.9) months). Median (IQR) time from cancer diagnosis to
suspected onset of ONJ was 60.2 (30.8–116.4) months (mean
[SD] was 83.3 [71.7] months).
The percentages of men and women in the study were
similar (49 versus 51%) and the median (IQR) age was 67
(59–74) years (Table 2). The mean (SD) age was 66.5 (10.8)
years. Most patients had breast cancer (37%; n = 120), pros-
tate cancer (25%; n = 81), or multiple myeloma (22%; n = 72).
Themajority of patients had an ECOG performance status of 0
or 1 (88%; n = 287). Of 228 patients with solid tumors, 91%
had stage 4 disease, whereas patients with multiple myeloma
most frequently had stage 3 disease (37%; n = 27). Fifty-six
percent of patients (n = 184) were current or former tobacco
users.
Medication use before development of ONJ
Nearly all patients (n = 318; 97%) had received antiresorptive
medication before development of ONJ; only 9 patients (3%)
had not received antiresorptive agents (Table 3). Of these 9
patients, 5 had exposure to a high-risk cancer medication such
as antiangiogenic agents or corticosteroids (Table 3), 7 had
prior tooth extractions, 7 had had no dental visits or cleanings
in the 12 months prior to ONJ onset, 3 were current or former
smokers, and 2 had medical comorbidities including diabetes
mellitus. Two hundred twenty-one patients (68%) had re-
ceived zoledronic acid, 125 (38%) had received denosumab,
and 31 (10%) had received pamidronate. Fifty-seven percent
of patients (n = 186) had received bisphosphonates only, 19%
(n = 63) had received denosumab only, and 21% of patients
(n = 69) had sequential exposure to both denosumab and
bisphosphonates (in either order). Median (IQR) duration of
antiresorptive medication before suspected ONJ onset was 27
(16–46) months; the mean (SD) duration was 34 (27) months.
The median (IQR) durations of denosumab, bisphosphonates,
or their combination before suspected ONJ onset were 15.7
(10.6–24.2) months for denosumab only, 26.2 (12.8–47.0)
months for patients on bisphosphonates only, and 40.0
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(27.6–60.8) months for patients who received denosumab and
bisphosphonates. The mean (SD) durations were 18.4 (12.5)
months for denosumab only, 35.6 (31.0) months for
bisphosphonates only, and 46.4 (31.4) months for patients
who received both.
In addition, other cancer medications that may have in-
creased risk for ONJ development included angiogenics/
tyrosine kinase inhibitors (bevacizumab, sunitinib, sorafenib,
or cabozantinib) in 37 patients (11%), protein kinase inhibitors
or other angiogenics in 46 patients (14%), and corticosteroids/
immunosuppressants in 45 patients (14%) (Table 3).
Compared to single agent therapy, patients exposed to both
denosumab and bisphosphonates did not present with higher
proportions of stage 3 ONJ or severe symptoms (grade 3;
National Cancer Institute Common Terminology Criteria for
Adverse Events [NCI CTCAE], version 4.03). Furthermore,
rates of associated local oral risk factors (such as tooth extrac-
tions) were similar in patients with combined exposure to
denosumab and bisphosphonates and those exposed to single
agent antiresorptives (Table 3). Following positive
adjudication of ONJ and enrollment in the registry, approxi-
mately 10 to 20% of enrolled patients continued to use
antiresorptive treatment at each post-enrollment time point;
65 patients (20%) were still receiving antiresorptive therapy
3 months after enrollment in the study. Less than 10% of
patients who were on study for ≥ 24 months continued
antiresorptive therapy.
Most patients (n = 246) discontinued treatment with
antiresorptive medications after 3 months. Patients that
discontinued antiresorptive treatment between baseline and
3 months had a higher percentage of stage 3 ONJ (11 versus
6%). Similarly, those patients (n = 65) who continued on
antiresorptive medications after 3 months had a higher per-
centage of stage 1 asymptomatic ONJ at baseline (32 versus
24%). Patients who continued on antiresorptive medications
had a slightly lower percentage of ONJ resolution (28 versus
37%). The median (IQR) time from ONJ onset to resolution
for patients who continued antiresorptives was 6.0 (4.0–10.3)
months; for patients who discontinued, the time was 7.7 (4.9–
11.5) months. The time to resolution of stage 1 asymptomatic
ONJ was similar between patients that continued
antiresorptive medication and those who discontinued treat-
ment. However, the overall numbers may be too small to draw
meaningful conclusions and these comparisons do not account
for other confounders such as ongoing cancer therapies. Few
patients (n = 3) were on antiresorptive treatment after
24 months. One patient was on zoledronic acid and two pa-
tients were on denosumab. One patient on denosumab had a
giant cell tumor of bone where the therapy discontinuation
risk outweighed the risk of ONJ. Before development of
ONJ, there were a variety of anticancer and antiresorptive
therapies administered to patients (Table 3).
Patient ONJ status at baseline
At baseline, most patients (58%; n = 191) had stage 2 ONJ per
the 2014 AAOMS guidelines (Table 4). The majority of pa-
tients had grade 2 (64%; n = 208) or grade 3 (6%; n = 19)
symptomatic ONJ according to CTCAE version 4.03 classifi-
cation of ONJ severity. Most patients had at least one ONJ
lesion in the mandible (Table 4). Oral risk factors associated
with ONJ included tooth extraction (47%; n = 155), periodon-
tal infection (10%; n = 34), and denture trauma (10%; n = 31);
no ONJ local oral risk factors were identified in 31% of pa-
tients (n = 100; i.e., nonspecified ONJ).
ONJ treatment patterns and outcomes
The majority of patients included in the registry (92%; n =
300) were treated with medication for ONJ (Table 5): 80%
(n = 263) received antibiotics and 59% (n = 192) received oral
rinses. Of the patients (31%; n = 102) whose ONJ was surgi-
cally managed, 55 patients (17%) were treated with minimally
Table 2 Baseline demographic and clinical characteristics
Characteristic Patients
(N = 327)
Median (IQR) age, years 67 (59–74)
Women, n (%) 167 (51)
ECOG performance status, n (%)
0 159 (49)
1 128 (39)
2 38 (12)
Median (IQR) months from cancer diagnosis to ONJ on-
set
60 (31–116)
Type of cancer, n (%)
Breast 120 (37)
Prostate 81 (25)
Myeloma 72 (22)
Renal 19 (6)
Non-small-cell lung cancer 11 (3)
Thyroid 4 (1)
Other* 16 (5)
Radiotherapy to the head and neck, n (%)
No 311 (95)
Yes 16 (5)
Curative intent 2 (1)
Palliative therapy 14 (4)
Previous or current tobacco user, n (%) 184 (56)
ECOG Eastern Cooperative Oncology Group, IQR interquartile range,
ONJ osteonecrosis of the jaw
*Includes colon, pancreatic, and sarcoma (n = 2 each) and cancer cardia
adenocarcinoma, chest wall squamous cell carcinoma, giant cell tumor of
bone, liver cancer, small-cell lung cancer, lymphoma, neuroendocrine
tumor, ovarian cancer, melanoma, and testicular cancer (n = 1 each)
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Table 3 Patient treatment before ONJ onset and stage at onset by antiresorptive regimen
Dmab only (n = 63) BP only (n = 186) Dmab + BP (n = 69) No antiresorptives (n = 9) All (N = 327)
Cancer medications, n (%)
Antineoplastic/chemotherapeutic agents 29 (46.0) 109 (58.6) 38 (55.1) 5 (55.6) 181 (55.4)
Hormonal agents/endocrine therapy 37 (58.7) 76 (40.9) 49 (71.0) 3 (33.3) 165 (50.5)
Other antineoplastic agents 6 (9.5) 55 (29.6) 3 (4.3) 4 (44.4) 68 (20.8)
Immunostimulants/immunomodulators 0 50 (26.9) 6 (8.7) 1 (11.1) 57 (17.4)
Other* 3 (4.8) 1 (0.5) 5 (7.2) 0 9 (2.8)
Antiresorptive medications, n (%)
Antiangiogenics† 8 (12.7) 18 (9.7) 10 (14.5) 1 (11.1) 37 (11.3)
Protein kinase inhibitors/other angiogenics 8 (12.7) 21 (11.3) 14 (20.3) 3 (33.3) 46 (14.1)
Corticosteroids/immunosuppressants 1 (1.6) 37 (19.9) 6 (8.7) 1 (11.1) 45 (13.8)
Duration of antiresorptive medication, months‡
< 6 8 (12.7) 18 (9.7) 3 (4.3) NA 23 (7.0)
≥ 6 to < 12 11 (17.5) 17 (9.1) 4 (5.8) 32 (9.8)
≥ 12 to < 24 25 (39.7) 48 (25.8) 10 (14.5) 83 (25.4)
≥ 24 to < 36 14 (22.2) 30 (16.1) 14 (20.3) 58 (17.7)
≥ 36 to < 48 3 (4.8) 29 (15.6) 16 (23.2) 48 (14.7)
≥ 48 to < 60 1 (1.6) 15 (8.1) 8 (11.6) 24 (7.3)
≥ 60 1 (1.6) 29 (15.6) 14 (20.3) 43 (13.1)
Type of cancer, n (%)
Breast 22 (34.9) 71 (38.2) 24 (34.8) 3 (33.3) 120 (36.7)
Prostate 25 (39.7) 26 (14.0) 29 (42.0) 1 (11.1) 81 (24.8)
Myeloma 0 70 (37.6) 1 (1.4) 1 (11.1) 72 (22.0)
Other 14 (22.2) 17 (9.1) 15 (21.7) 4 (44.4) 50 (15.3)
Stage at onset, n (%)
Resolved 1 (1.7) 3 (1.6) 3 (4.4) 0 7 (2.1)
Stage 1 13 (20.6) 50 (26.9) 18 (26.1) 5 (55.6) 86 (26.3)
Stage 2 43 (68.3) 103 (55.4) 41 (59.4) 4 (44.4) 191 (58.4)
Stage 3 6 (9.5) 23 (12.4) 5 (7.2) 0 34 (10.4)
Unknown 0 7 (3.8) 2 (2.9) 0 9 (2.8)
Local oral risk factors§, n (%)
Tooth extraction 27 (42.9) 92 (49.5) 31 (44.9) 5 (55.6) 155 (47.4)
No identified factors 23 (36.5) 60 (32.3) 15 (21.7) 2 (22.2) 100 (30.6)
Periodontal infection 7 (11.1) 17 (9.1) 10 (14.5) 0 34 (10.4)
Denture trauma 6 (9.5) 15 (8.1) 9 (13.0) 1 (11.1) 31 (9.5)
Dental or oral surgery 5 (7.9) 12 (6.5) 7 (10.1) 1 (11.1) 25 (7.6)
Dental decay 0 3 (1.6) 1 (1.4) 0 4 (1.2)
Dental implant surgery 0 1 (0.5) 1 (1.4) 0 2 (0.6)
Other|| 3 (4.8) 14 (7.5) 9 (13.0) 0 26 (8.0)
BP bisphosphonate, Dmab denosumab, NA not applicable, ONJ osteonecrosis of the jaw
*Other medications include investigational products (n = 5)
†Antiangiogenic therapies include bevacizumab, sunitinib, sorafenib, and cabozantinib
‡ 16 patients were not on antiresorptive agents before the onset of ONJ
§ Patients could be counted in more than one category
|| BOther^ included bony exostosis, embedded tooth, exposed molar root mobile molar (right side), gingival inflammation, grossly decayed, injury after
eating hard food, lingual torus, multiple decayed and unrestorable teeth mandibular component, mylohyoid region (anatomical predisposed region),
injury, restant tooth roots potentially infecting area, self-expoliation, slight discomfort to the lateral border of the tongue, smoking, splint wear, the tooth
has fallen by itself, undernourishment
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invasive sequestrectomy and 32 patients (10%) were treated
with debridement. Fifteen patients (5%) had resection with or
without jaw reconstruction. Most (7/11) patients who
underwent jaw resection without reconstruction had stage 2
ONJ lesions. All four patients who underwent jaw resection
requiring reconstruction did so for progression to stage 3 ONJ
lesions. The majority of patients who required surgery also
received antibiotics (96 patients, 94%).
Antibiotic regimens and average treatment durations are
shown in Table 6. The most commonly used antibiotic class
was extended-spectrum penicillins (212 courses). Doses of
antibiotic therapy varied, although the doses were reflective
of standard dose regimens. Two-hundred sixty-three (80%)
patients received 840 courses of antibiotics. The majority of
patients required more than one course of therapy: 37% re-
ceived a single course, 44% received 2–4 courses, and 19%
received ≥ 5 courses. The average duration of antibiotic use
was 28 days.
Last available ONJ status stratified by stage at baseline
(AAOMS), type of antiresorptive exposure, and ONJmanage-
ment strategy are listed in Table 7. Outcomes of ONJ accord-
ing to AAOMS staging criteria, NCI CTCAE ONJ severity,
ONJ lesion size grading (using guidelines provided by
Weitzman et al., 2007 [45]), and clinical impression are sum-
marized in Table 8. In total, 55 to 69% of evaluable patients
had resolution or improvement during the study (Table 8). A
further 18 to 26% of patients were considered stable, and a
smaller proportion of patients had ONJ progression (5–14%;
Table 8). ONJ resolution was observed in 114 patients (35%),
with the median (IQR) time from ONJ onset to resolution
being 7.3 (4.5–11.4) months. Of these 114 patients, 43
(38%) underwent surgical procedures and the remainder (71
patients [62%]) were managed conservatively with medica-
tions only). Of the 34 patients with stage 3 ONJ at baseline,
Table 4 Baseline ONJ status at enrollment
Overall (N = 327)
AAOMS ONJ staging, n (%)
Stage 1 86 (26)
Stage 2 191 (58)
Stage 3 34 (10)
Unknown 9 (3)
Resolved* 7 (2)
NCI CTCAE ONJ severity, n (%)
Grade 1 (asymptomatic) 85 (26)
Grade 2 (symptomatic) 208 (64)
Grade 3 (severe symptoms) 19 (6)
Unknown 8 (2)
Resolved* 7 (2)
Lesion location,† n (%)
Mandible, teeth, and lateral jaw 231 (71)
Mandible, medial jaw 30 (9)
Maxilla, teeth, and lateral jaw 77 (24)
Maxilla, medial jaw 6 (2)
Maxilla, hard palate 2 (1)
AAOMS American Association of Oral and Maxillofacial Surgeons, NCI
CTCAE National Cancer Institute Common Terminology Criteria for
Adverse Events, ONJ osteonecrosis of the jaw
*Patients whose ONJ resolved between screening and enrollment
† Patients could be counted in more than one category
Table 5 Summary of ONJ treatment
Treatment, n (%) Patients (N = 327)
Patients treated with medications 300 (92)
Antibiotics 263 (80)
Oral rinses* 192 (59)
Pain medications† 27 (8)
Antifungal/antimycotic 8 (2)
Other 40 (12)
Patients treated with surgical procedures 102 (31)
Sequestrectomy 55 (17)
Debridement 32 (10)
Resection with or without jaw reconstruction 15 (5)
Curettage 13 (4)
Tooth extraction (as treatment for ONJ) 6 (2)
Other‡ 8 (2)
ONJ osteonecrosis of the jaw
*Oral rinse active ingredients by frequency of use were chlorhexidine,
sodium hypochlorite, isobetadine, and urea hydrogen peroxide
† Includes opioid and nonopioid pain medications
‡ Includesmucosal reconstruction with buccinators flap, flap, selectivemill-
ing flapless (without surgery), reoperation microanastomoses, radical left
mandibulectomy, microvenous anastomoses recovery, osteotomy, fistula
excision, replacement of fractual reconstruction plate (patients may have
had multiple procedures), and removal of fractured lower left mandible
Table 6 Antibiotic regimens and duration of treatment
Antibiotic class/category Courses, n (%) Average duration, d
Extended-spectrum penicillin 212 (25.2) 48.8
Amoxicillin-clavulanic acid 175 (20.8) 26.6
Tetracyclines 119 (14.2) 10.4
Clindamycin 99 (11.8) 11.1
Metronidazole 96 (11.4) 17.4
Penicillin VK 50 (6.0) 40.7
Cephalosporins 21 (2.5) 27.7
Fluoroquinolone 20 (2.4) 63.3
Macrolide 19 (2.3) 27.3
Ampicillin-sulbactam 15 (1.8) 39.4
Vancomycin 12 (1.4) 17.3
Aminoglycoside 1 (0.12) 15.0
Trimethoprim-sulfamethoxazole 1 (0.12) 16.0
Total 840 28.2
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12 (35%) had ONJ resolution at the last post-baseline ONJ
staging, comparable to the overall ONJ resolution rate.
Discussion
Most patients enrolled in this large international registry study
had AAOMS stage 2 ONJ and CTCAE grade 2 (symptomatic)
ONJ severity at baseline. The median time from cancer
diagnosis to suspected ONJ onset was 60.2 months. Nearly
all patients (95%) with positively adjudicated ONJ in this
registry had received antiresorptive medication before the on-
set of ONJ, including denosumab and/or bisphosphonates,
with a median duration of treatment of 27.2 months. Of the
16 patients who did not receive antiresorptive medications, 4
received protein kinase inhibitors and 1 received immunosup-
pressants. Many patients had other local oral risk factors as-
sociated with the development of ONJ, with tooth extraction
Table 7 ONJ resolution by baseline staging and management
Characteristic Outcome, n (%) Total
(N = 327)
Resolved
(n = 114)
Improved
(n = 50)
Progression
(n = 19)
Stable
(n = 83)
Not evaluable
(n = 61)
Stage at enrollment*
Resolved† 5 (1.5) 2 (0.6) 0 (0.0) 0 (0.0) 0 (0.0) 7 (2.1)
1 28 (8.6) 44 (13.5) 14 (4.3) 0 (0.0) 0 (0.0) 86 (26.3)
2 67 (20.5) 45 (13.8) 74 (22.6) 5 (1.5) 0 (0.0) 191 (58.4)
3 12 (3.7) 1 (0.3) 3 (0.9) 18 (5.5) 0 (0.0) 34 (10.4)
Not evaluable‡ 2 (0.6) 3 (0.9) 2 (0.6) 0 (0.0) 2 (0.6) 9 (2.8)
Total 114 (34.9) 95 (29.1) 93 (28.4) 23 (7.0) 2 (0.6) 327 (100.0)
Antiresorptive therapy at baseline
Denosumab only 26 (41.3) 10 (15.9) 1 (1.6) 14 (22.2) 12 (19.0) 63 (19.3)
Bisphosphonates only 66 (35.5) 26 (14.0) 12 (6.5) 47 (25.3) 35 (18.8) 186 (56.9)
Denosumab plus bisphosphonate 18 (26.1) 13 (18.8) 5 (7.2) 19 (27.5) 14 (20.3) 69 (21.1)
No antiresorptives 4 (44.4) 1 (11.1) 1 (11.1) 3 (33.3) 0 9 (2.8)
Outcomes by management
Medications only 63 (31.0) 29 (14.3) 10 (4.9) 50 (24.6) 51 (25.1) 203 (62.1)
Medication and surgery 40 (41.2) 21 (21.6) 7 (7.2) 26 (26.8) 3 (3.1) 97 (29.7)
Surgery only 3 (60.0) 0 0 1 (20.0) 1 (20.0) 5 (1.5)
No treatment 8 (36.4) 0 2 (9.1) 6 (27.3) 6 (27.3) 22 (6.7)
*2014 AAOMS staging
† Patients whose ONJ resolved during the lag time between screening and enrollment. For all criteria, resolution was defined as complete coverage of the
exposed bone by mucosa in the absence of clinical symptoms; improvement, progression, and stable were defined by comparing a patient’s initial ONJ
stage with that at the last available assessment
‡ Patients without any follow-up assessments after enrollment were coded as Bnot evaluable^
Table 8 Summary of ONJ outcomes
Outcome, n (%) (N = 327) AAOMS ONJ staging NCI CTCAE ONJ severity Clinical impression ONJ lesion size [45]
Resolved* 114 (35) 114 (35) 115 (35)† 114 (35)
Improved 50 (15) 59 (18) 52 (16) 32 (10)
Progression 19 (6) 16 (5) 45 (14) 36 (11)
Stable 83 (25) 77 (24) 59 (18) 84 (26)
Not evaluable‡ 61 (19) 61 (19) 56 (17) 61 (19)
AAOMSAmerican Association of Oral andMaxillofacial Surgeons,NCI CTCAECommon Terminology Criteria for Adverse Events,ONJ osteonecrosis
of the jaw
*For all criteria, resolution was defined as complete coverage of the exposed bone by mucosa in the absence of clinical symptoms; improvement,
progression, and stable were defined by comparing a patient’s initial ONJ stage with that at the last available assessment
†One patient was considered to have ONJ that had resolved by clinical impression but not by stage, severity, and grade
‡ Patients without any follow-up assessments after enrollment were coded as Bnot evaluable^
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being the most frequent (47%); however, 31% of patients had
no notable ONJ risk factors (i.e., nonspecified ONJ). ONJ
treatment among patients enrolled in the study was largely
conservative, with most patients (92%) receiving medications
(e.g., antimicrobial oral rinses and/or antibiotics). Thirty-one
percent of patients required limited surgical procedures to treat
ONJ (e.g., debridement, sequestrectomy, curettage). ONJ res-
olution was observed in 35% of patients (median follow-up
time of 11 months) and overall, more than half of patients in
the study had resolution or improvement of ONJ.
The definition of ONJ has changed in recent years. The
original AAOMS definition centered on medication-induced
exposure of bone; however, the revised classification includes
bone that can be probed through a fistulous tract in the absence
of exposed bone (i.e., nonexposed variant) [10]. These chang-
es arose from studies that presented patients with fistulas or
even patients without fistulas and no bone exposure [13–15].
When our study was initiated, the older definition was in use;
however, the study was modified to include patients without
bone exposure when the definition was updated.
Resolution of ONJ was observed in approximately one
third of evaluable patients, with a median time to resolution
of 7.3 months (time to resolution varied widely). If the lesions
recurred (n = 14), they were not reported as resolved.
Although this is an interim study and the full results will
provide more information on the rate and time course for
treatment outcomes, the findings were similar to those previ-
ously reported in patients with advanced cancer and bone
metastases treated with bone-targeted agents. In previous stud-
ies, approximately 18 to 50% of patients treated with
denosumab and 8 to 43% of patients treated with
bisphosphonates had resolution of the ONJ event [21, 22,
44]. Of the 114 patients whose ONJ lesions resolved, 43
(38%) underwent surgical procedures and the remainder (71
patients [62%]) were managed conservatively with medica-
tions only. Resolution of ONJ also varied by type of
antiresorptive therapy at baseline; patients who received
denosumab only had higher rates of resolution and lower rates
of progression compared with those who received zoledronic
acid only. The duration of antiresorptive therapy before ONJ
also varied, with a shorter duration for denosumab compared
with zoledronic acid. However, it should be noted that imbal-
ances in baseline characteristics were observed; for example,
there were more patients with prostate cancer who received
denosumab only (40%) than zoledronic acid only (14%), and
there were a greater number of patients with stage 3 ONJ in the
zoledronic acid cohort compared with denosumab (Table 3). It
has been observed that patients with prostate cancer typically
experience shorter time to ONJ compared to patients with
breast cancer and longer time to resolution; these patients are
also more likely to be older, have more comorbidities, and
receive higher doses of corticosteroids compared with patients
with breast cancer [46]. Because this trial was not designed
with the expectation or statistical plan to account for differ-
ences in tumor types, such differences in baseline characteris-
tics may confound final interpretation of the data. In fact, data
from open-label extension studies have demonstrated no dif-
ference in the rates of ONJ between patients receiving
denosumab or zoledronic acid [46].
The ONJ resolution rate in this registry study (35%) is very
similar to that reported in an integrated analysis of three SRE
prevention studies in patients with bone metastases secondary
to breast cancer, prostate cancer, or myeloma (36%; median
follow-up of 13 months) [25] and in an extension (up to 2
additional years) combining the breast and prostate cancer
SRE prevention studies (36%) [46]. The median cumulative
denosumab exposure in the extensions was 43 months for
breast cancer and 37 months for prostate cancer groups [47].
Many patients had risk factors for ONJ other than
antiresorptive therapy exposure. These risk factors included
tooth extraction/dental procedure and therapy with
antiangiogenics or immunosuppressants, as well as dental/
periodontal infection and dental trauma. Thirty-one percent
of patients had no identified local oral risk factors for ONJ.
Reported rates of spontaneous ONJ range from 19 to 41% of
studies with at least 100 patients exposed to bisphosphonates,
which is consistent with our analysis [37, 48].
Notably, because even minor trauma, such as intubation or
impression tray lesions, may lead to ONJ [37], it is possible
that such factors were overlooked and thus not included in
patients’ charts or dental records. In the Copenhagen cohort
of 149 patients, 64%were reported to have ONJ attributable to
tooth extraction or dental trauma [37]; this is similar to the rate
of 57% reported in the present study. It is also possible that
other factors, such as viral infections [49], may have been
overlooked and therefore not captured as possible risk factors.
At baseline, approximately two thirds of patients had stage
2 ONJ and were symptomatic, and the majority of patients
(95%) received antiresorptive medication for a median of
27 months before ONJ onset. In previous studies, patients
with an increased time of exposure to antiresorptive agents
and those with a history of tooth extractions were also at
greater risk of developing ONJ [17, 21, 22, 24, 31, 34, 44].
Furthermore, the duration of treatment with bone-targeted
agents before the onset of ONJ in previous studies was similar
to that seen in our study [17, 24, 34]. ONJ also appeared more
frequently in the mandible than in the maxilla, which was
consistent with previously reported findings [16, 17, 24, 30,
34, 50].
The key strength of this study is that this case registry
report examined the effect of these therapies on ONJ in a
substantial number of patients with advanced cancer and ex-
amined additional local oral and medication ONJ risk factors,
as well as the treatment and management of ONJ and patient
outcomes. Most previously published findings on medication-
related ONJ have been based on small cohorts of patients or
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systematic reviews or integrated analyses of previously report-
ed studies [4, 11, 17, 24, 25, 29, 33, 34].
This study had limitations. The study did not contain
matched groups in which one group continued medication
use and the other discontinued medication during the ONJ
treatment period. Thus, it was not possible to evaluate patterns
of resolution or recurrence after cessation or continuation of
medication. Additionally, this study does not provide informa-
tion about when to reinitiate medication after ONJ resolution.
Finally, this study was observational in nature, and compari-
son between patients who received different antiresorptive
treatments may be confounded by indication.
In summary, depending on the ONJ assessment tool used,
up to 69% of evaluable patients had improvement or resolu-
tion of their ONJ event. These results are consistent with those
observed in clinical trials evaluating SREs in patients with
advanced malignancy involving bone. Longer follow-up will
provide further information on important clinical questions
such as recurrent ONJ and ONJ resolution rates between med-
ically and surgically managed patients.
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